Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Examination of DPY-30, DPY-27, SDC-3, DPY-26, MIX-1, SMC-4, ASH-2, RNA Polymerase II binding in wild type and DCC mutant embryos


ABSTRACT: Here we exploit the essential process of X-chromosome dosage compensation to elucidate basic mechanisms that control the assembly, genome-wide binding, and function of gene regulatory complexes that act over large chromosomal territories. We demonstrate that a subunit of C. elegans MLL/COMPASS, a gene-activation complex, acts within the dosage compensation complex (DCC), a condensin complex, to target the DCC to both X chromosomes of hermaphrodites and thereby reduce chromosome-wide gene expression. The DCC binds to two categories of sites on X: rex sites that recruit the DCC in an autonomous, sequence- dependent manner, and dox sites that reside primarily in promoters of expressed genes and bind the DCC robustly only when attached to X. We find that DCC mutants that abolish rex-site binding do not eliminate dox-site binding, but instead reduce it to the level observed at autosomal binding sites in wild-type animals. Changes in DCC binding to these non-rex sites occur throughout development and correlate with transcriptional activity of adjacent genes. Moreover, autosomal DCC binding is enhanced by rex-site binding in cis in X-autosome fusion chromosomes. Thus, dox and autosomal sites exhibit similar binding properties. Our data support a model for DCC binding in which low-level DCC binding at dox and autosomal sites is dictated by intrinsic properties correlated with high transcriptional activity. Sex-specific DCC recruitment to rex sites then greatly elevates DCC binding to dox sites in cis, which lack intrinsically high DCC affinity on their own. We also show here that the C. elegans DCC achieves dosage compensation through its effects on transcription. ChIP-chip experiments using antibodies against DPY-27, SDC-3, DPY-30, DPY-26, MIX-1, SMC-4, ASH-2 in wild-type embryos. ChIP-chip experiments using antibodies against SDC-3, DPY-27, DPY-30, ASH-2, and IgG in different DCC mutants. ChIP-chip experiments using antibodies against RNA Pol II (hypophosphorylated and S2 and S5) in wild type and sdc-2 partial loss of function mutants.

ORGANISM(S): Caenorhabditis elegans

SUBMITTER: Barbara Meyer 

PROVIDER: E-GEOD-25833 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

An MLL/COMPASS subunit functions in the C. elegans dosage compensation complex to target X chromosomes for transcriptional regulation of gene expression.

Pferdehirt Rebecca R RR   Kruesi William S WS   Meyer Barbara J BJ  

Genes & development 20110301 5


Here we analyze the essential process of X-chromosome dosage compensation (DC) to elucidate mechanisms that control the assembly, genome-wide binding, and function of gene regulatory complexes that act over large chromosomal territories. We demonstrate that a subunit of Caenorhabditis elegans MLL/COMPASS, a gene activation complex, acts within the DC complex (DCC), a condensin complex, to target the DCC to both X chromosomes of hermaphrodites for chromosome-wide reduction of gene expression. The  ...[more]

Similar Datasets

2009-03-07 | E-GEOD-14649 | biostudies-arrayexpress
2011-03-01 | E-GEOD-25877 | biostudies-arrayexpress
2013-08-31 | E-GEOD-48413 | biostudies-arrayexpress
2011-03-01 | GSE25833 | GEO
2011-03-01 | E-GEOD-25834 | biostudies-arrayexpress
2011-03-01 | GSE25877 | GEO
2010-05-22 | E-GEOD-14651 | biostudies-arrayexpress
2010-05-22 | E-GEOD-14653 | biostudies-arrayexpress
2010-05-22 | E-GEOD-14650 | biostudies-arrayexpress
2009-03-01 | GSE14651 | GEO